The reporting Member States and the Member States concerned shall:
support the safety assessing Member State in the coordinated safety assessment and have the possibility to comment and raise queries on the assessments;
take due account of safety concerns in relation to an investigational medicinal product and recommendations by the safety assessing Member State, referred to in Article 8(2), in the context of clinical trial(s) authorised in their territory;
communicate to the safety assessing Member State any relevant safety concerns related to the active substance.
The reporting Member State(s):
shall inform existing safety assessing Member States about the authorisation of a new clinical trial involving the same active substance;
shall verify if there is an existing safety assessing Member State for any active substance used in a clinical trial and, if that is not the case, launch and conduct a selection procedure in accordance with Article 3(2). In order to ensure continuity in safety assessment at any time, the reporting Member State shall carry out the tasks of the safety assessing Member State during the selection process;
may request support from the safety assessing Member State for the assessment of changes to the reference safety information when the safety assessing Member State is not a Member State concerned with the clinical trial, in accordance with article 5(1), point (c).
Member States shall jointly develop a good practice guidance describing detailed procedures for safety cooperation including corresponding timelines and the content of the assessment reports.
Member States may coordinate and facilitate safety surveillance and oversight, related to the active substance, across clinical trials.